Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) have been assigned a consensus recommendation of “Hold” from the thirty-one brokerages that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a sell rating, nineteen have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $37.07.

A number of brokerages have commented on TEVA. Zacks Investment Research cut shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “strong sell” rating in a research note on Wednesday. Deutsche Bank AG restated a “buy” rating and set a $28.00 price target (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday. Jefferies Group LLC restated a “hold” rating and set a $26.00 price target (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price target (down previously from $31.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday. Finally, Credit Suisse Group restated an “outperform” rating and set a $39.00 price target on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday.

TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given Consensus Rating of “Hold” by Brokerages” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-nyseteva-given-consensus-rating-of-hold-by-brokerages/1479883.html.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up 0.64% during trading on Friday, hitting $17.30. The stock had a trading volume of 25,100,576 shares. Teva Pharmaceutical Industries Limited has a 52 week low of $16.81 and a 52 week high of $55.39. The company’s market cap is $17.58 billion. The stock has a 50-day moving average price of $29.64 and a 200-day moving average price of $31.56.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.25 EPS. Equities analysts predict that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be issued a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 1.97%. The ex-dividend date of this dividend is Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -18.95%.

A number of hedge funds have recently added to or reduced their stakes in the company. Cribstone Capital Management LLC boosted its position in shares of Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock worth $101,000 after buying an additional 100 shares in the last quarter. Bronfman E.L. Rothschild L.P. boosted its position in shares of Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after buying an additional 261 shares in the last quarter. Kistler Tiffany Companies LLC boosted its position in shares of Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after buying an additional 1,571 shares in the last quarter. FNY Managed Accounts LLC purchased a new position in shares of Teva Pharmaceutical Industries Limited during the first quarter worth $123,000. Finally, Sterling Investment Advisors Ltd. boosted its position in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares in the last quarter. 56.27% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.